Phase 2 of the Cité de la Biotech de Laval: investments of $ 1 billion and 7,500 new jobs

Advertisement

The launch of phase 2 of the Cité de la Biotech de Laval will generate investments of $ 1 billion over 10 years in companies which notably develop vaccines, a key word in the midst of a pandemic.

Advertisement

Two decades after the creation of this science park covering 1.3 million square meters, within a radius of 3 km, the private sector has made investments of $ 4.5 billion.

The addition of 100,000 square meters of land to be developed will make it possible to accommodate companies in the life sciences sector on the site of the National Institute for Scientific Research (INRS). We want to create 7,500 new jobs and accentuate the synergy between companies, researchers and employees.

Advertisement

These sought-after companies, which will be able to take advantage of tax credit programs, work mainly in the biomedicines sector, which includes vaccines, antibodies, proteins and cell therapies, it was explained in a statement on Wednesday.

“This structuring project undoubtedly meets the City’s objectives with regard to economic recovery and the acceleration of major projects. Located near a metro station and the city center, phase II of the Cité de la Biotech is the perfect place to offer businesses and workers an inspiring and innovative living environment, in continuity with the current site. ”, Said Stéphane Boyer, deputy mayor of Laval and vice-president of the executive committee.

Advertisement
ALSO READ  Quebec is increasing its aid to support businesses affected by COVID-19

The Cité de la Biotech brings together 5,500 jobs in more than 110 companies and institutions. It includes the Quebec Biotechnology Innovation Center (CQIB), the first biotech incubator in Canada created a quarter of a century ago, as well as the Armand-Frappier Health Biotechnology Center at INRS. Firms like Sanofi, GSK, Bausch Health, Roche, Servier, Charles River, Altasciences and Bio-K + are also established there.

“INRS is proud to join forces with the City of Laval to promote the development of high-tech companies. This initiative fits perfectly into our mission to contribute to the development of our company through research. Phase II of the Cité de la Biotech will enable INRS teams to increase research partnerships in key sectors at the present time, ”said Luc-Alain Giraldeau, Director General of INRS.

Advertisement

.

Advertisement

Advertisement

Leave a Reply

Your email address will not be published.